Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shanghai Henlius Announces $192.5 Million Funding for Biosimilars, Novel mAbs

publication date: Dec 29, 2017

Shanghai Henlius Biotech boosted its cash level by selling 55.4 million shares to bring in $192.5 million. Shanghai Henlius, a joint venture formed by Henlius Biotech and Shanghai Fosun Pharma in 2009, is developing a portfolio of biosimilars, bio-betters and novel biotech drugs. Fosun contributed $50 million to the fundraising, giving it a 62% majority stake in Shanghai Henlius after the offering. Henlius says it has submitted eight INDs to the CFDA with thirteen indications. Its two lead drugs have started Phase III trials. More details....

Stock Symbols: (SHA: 600196; HK: 2196)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here